Overcoming Resistance to EGFR inhibitor in Head and Neck Squamous Cell Carcinoma

点击翻译按钮获取中文摘要

Despite advances in the management of head and neck squamous cell carcinoma (HNSCC) patients, the survival has not been significantly improved. Therefore, the search for potential alterative therapies is encouraging. In the current study, we examined the effect of deguelin, a rotenoid from the African plant Mundulea sericea on head and neck squamous cell carcinoma cell lines. The results demonstrated that deguelin induced apoptosis by inhibiting constitutive and EGF-stimulated AKT activation. We further demonstrated that deguelin inhibited IGF1R-AKT pathway.Cetuximab, antibody of EGFR, is an applicable for HNSCC therapy. However, a mechanism of cetuximab resistance for HNSCC is thought to be IGF1R-AKT signaling in addition to EGFR-AKT pathway. Therefore, these results suggested that deguelin may overcome resistance to EGFR inhibitor in HNSCC. Further work is needed.